II. Epidemiology
III. Pathophysiology
-
Portal Hypertension
- Results in increased splanchnic Blood Volume with increased nitric oxide production
- Secondary splanchnic and arterial vasodilation
-
Kidneys sense decreased perfusion
- Activates Renin-Angiotensin System
- Results in increased Sodium and water retention
- Hypoalbuminemia and decreased oncotic pressure
- Increased splanchnic pressure overcomes oncotic pressure
- Transudate leaks into peritoneum
IV. Evaluation
- See Paracentesis
- Diagnostic Paracentesis Indications
- Exclude Spontaneous Bacterial Peritonitis (keep a low threshold for evaluation)
- Exclude extrahepatic causes of Ascites (see Ascites)
- Unexplained Ascites
- New onset Ascites
- Hospitalized patients
- Clinical deterioration
-
Ascites characteristics
- Portal Hypertension (Cirrhosis)
- Serum Albumin - Ascites Albumin exceeds 1.1 mg/dl
- Ascites not due to Portal Hypertension
- Albumin gradient (see above) <1.1 mg/dl
- Consider other Ascites Causes
- Peritoneal carcinomatosis
- Abdominal Tuberculosis
- Spontaneous Bacterial Peritonitis
- Ascitic Fluid Culture (at least 20 ml fluid)
- Split between 2 culture bottles (10 ml each), one aerobic and one anaerobic
- False Negative in 60% of cases
- Ascitic Fluid cell count and differential
- Total White Blood Cells (WBC ,Leukocytes) > 500/mm3
- Neutrophils (PMNs) > 250/mm3
- Test Sensitivity and Test Specificity: 93-94%
- Ascitic Fluid Culture (at least 20 ml fluid)
- Portal Hypertension (Cirrhosis)
V. Differential Diagnosis
- See Ascites Causes
VI. Management: Medical Management
- See Spontaneous Bacterial Peritonitis
-
Sodium restriction
- Maximum salt intake: 2 grams per day
- Salt Restriction controls Ascites in 10-20% patients
-
Diuretics
- Spironolactone (Aldactone)
- Start 25-50 mg three times daily to four times daily (max 100 mg/day in divided dosing)
- Increase as needed by 100 mg every 3 days (max 400 mg/day in divided dosing)
- Effective in 40-75% of cases
- Furosemide (Lasix)
- Start 40 mg orally daily
- Increase as needed up to 160 mg/day in divided dosing (e.g. twice daily)
- Goal
- Urine Sodium exceeds Urine Potassium
- Do not allow Serum Creatinine to rise over 3.0
- Contraindications (reasons to avoid, decrease or eliminate Diuretics
- Hyponatremia <125 meq/L
- Hypokalemia
- Hyperkalemia
- Acute Kidney Injury
- Severe Muscle cramps
- Spironolactone (Aldactone)
- Fluid Restriction
- Indicated for Serum Sodium <125 meq/L
- Limit to 1 to 1.5 L/day maximum if indicated
- Avoid provocative agents
- Avoid NSAIDs (increase renal Sodium retention)
- Avoid Beta Blockers, ACE Inhibitors and Angiotensin Receptor Blockers
- Associated with increased Hypovolemia and Hypotension risk
- Prophylactic Antibiotics (for prevention of Spontaneous Bacterial Peritonitis)
- Indications
- Liver failure (Child-Pugh Score >=9 and Serum Bilirubin >= 3 mg/dl)
- Renal dysfunction (Serum Creatinine >=1.2 mg/dl) or Hyponatremia (Serum Sodium <130 mEq/L)
- Ascitic fluid Protein <15 g/L
- Protocol
- Ciprofloxacin 400 mg orally daily
- Indications
VII. Management: Interventions
- Therapeutic Paracentesis Indications
- Required in up to 10% of cases
- Up to 4-6 liters may be safely removed per Paracentesis without albumin replacement
- Risk of Paracentesis-induced circulatory dysfunction (PICD) with large volume Paracentesis
- Replace albumin if >6 Liters are removed
- Give 6 to 8 g/L of Ascites removed
- Indications
- Significant patient discomfort (tense Ascites)
- Respiratory compromise
- Large Umbilical Hernia
- Recurrent Bacterial peritonitis
- Refractory Ascites
- Mortality approaches 20% in 6 months
- Consider Palliative Care referral if not a Liver Transplant candidate
- Temporizing measures
- Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- Peritoneovenous Shunt
- Liver Transplantation
- Mortality approaches 20% in 6 months
VIII. Prognosis
- Associated with increased mortality risk
- Poor prognostic sign for Cirrhosis course
IX. Complications
- Spontaneous Bacterial Peritonitis
- Umbilical Hernia with risk of rupture
X. References
- Swencki (2015) Crit Dec Emerg Med 29(11):2-10
- Garcia (2001) Postgrad Med 109(2):91-103 [PubMed]
- Keating (2022) Am Fam Physician 105(4): 412-20 [PubMed]
- Zervos (2001) Am J Surg 181(3):256-64 [PubMed]